Virus validation studies of immunoglobulin preparations

Area of Science:

• Immunology
• Virology
• Pharmaceutical Science

Background:

• Intravenous immunoglobulin (IVIG) therapy is crucial for treating various immune deficiencies.
• Ensuring the viral safety of IVIG products is paramount to patient health.
• Regulatory guidelines mandate rigorous viral clearance validation for blood-derived products.

Purpose of the Study:

• To validate the viral safety of a new polyvalent intravenous immunoglobulin (OCTAGAM).
• To assess the efficacy of specific manufacturing steps in reducing viral load.
• To comply with EU guidelines and German regulatory requirements for viral safety.

Main Methods:

• Analysis of viral reduction factors across multiple processing steps: Cohn-Oncley fractionation, solvent/detergent (SD) treatment, pH 4 exposure, and immune neutralization.
• Testing with a panel of enveloped (e.g., HIV-1, Sindbis virus, pseudorabies virus) and non-enveloped viruses (e.g., coxsackievirus-B6, poliovirus-1, SV40, HAV).
• Calculation of overall virus reduction factors for the final OCTAGAM product.

Main Results:

• Cohn-Oncley fractionation demonstrated significant reduction factors for most tested viruses.
• Solvent/Detergent (SD) treatment and pH 4 exposure showed substantial reduction, particularly for enveloped viruses.
• The final OCTAGAM product achieved high overall virus reduction factors, exceeding 20 for HIV-1 and pseudorabies virus.

Conclusions:

• Solvent/Detergent treatment and pH 4 exposure are critical steps in ensuring the viral safety of OCTAGAM.
• These steps, in conjunction with Cohn fractionation and immune neutralization, provide robust protection against both enveloped and non-enveloped viruses.
• The validation studies confirm OCTAGAM's safety profile concerning viral contamination.